0000000000477439
AUTHOR
T. Nguyen
Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1–6 Hepatitis C Virus Infections and Compensated Liver Disease
Background: Untreated, chronic hepatitis C virus (HCV) infection may lead to progressive liver damage, which can be mitigated by successful treatment. This integrated analysis reports the safety, efficacy, and pharmacokinetics (PK) of the ribavirin-free, direct-acting, antiviral, fixed-dose combination of glecaprevir/pibrentasvir (G/P) in patients with chronic HCV genotype 1-6 infections and compensated liver disease, including patients with chronic kidney disease stages 4 or 5 (CKD 4/5). Methods: Data from 9 Phase II and III clinical trials, assessing the efficacy and safety of G/P treatment for 8-16 weeks, were included. The presence of cirrhosis was determined at screening using a liver …
Measurement of CP asymmetry in Bs0 → Ds ∓K± decays
Journal of high energy physics 2018(3), 59 (2018). doi:10.1007/JHEP03(2018)059
TH-302 + Gemcitabine (G + T) vs Gemcitabine (G) in Patients with Previously Untreated advanced Pancreatic Cancer (PAC)
ABSTRACT Background TH-302 is a hypoxia targeted prodrug with a hypoxia-triggered 2-nitroimidazole component designed to release the DNA alkylator, bromo-isophosphoramide mustard (Br-IPM), when reduced in severe hypoxia. A randomized Phase 2B study (NCT01144455) was conducted to assess the benefit of G + T to standard dose G as first-line therapy of PAC. Materials and methods An open-label multi-center study of two dose levels of TH-302 (240 mg/m2 or 340 mg/m2) in combination with G versus G alone (randomized 1:1:1). G (1000 mg/m2) and T were administered IV over 30-60 minutes on Days 1, 8 and 15 of a 28-day cycle. Patients on the G could crossover after progression and be randomized to a G…
Observation of $Z$ production in proton-lead collisions at LHCb
The first observation of $Z$ boson production in proton-lead collisions at a centre-of-mass energy per proton-nucleon pair of $\sqrt{s_{NN}}=5~\text{TeV}$ is presented. The data sample corresponds to an integrated luminosity of $1.6~\text{nb}^{-1}$ collected with the LHCb detector. The $Z$ candidates are reconstructed from pairs of oppositely charged muons with pseudorapidities between 2.0 and 4.5 and transverse momenta above $20~\text{GeV}/c$. The invariant dimuon mass is restricted to the range $60-120~\text{GeV}/c^2$. The $Z$ production cross-section is measured to be \begin{eqnarray*} ��_{Z\to��^+��^-}(\text{fwd})&=&13.5^{+5.4}_{-4.0}\text{(stat.)}\pm1.2\text{(syst.)}~\text{nb} …
Multimessenger search for sources of gravitational waves and high-energy neutrinos: Initial results for LIGO-Virgo and IceCube
Made available in DSpace on 2022-04-29T07:21:49Z (GMT). No. of bitstreams: 0 Previous issue date: 2014-11-17 We report the results of a multimessenger search for coincident signals from the LIGO and Virgo gravitational-wave observatories and the partially completed IceCube high-energy neutrino detector, including periods of joint operation between 2007-2010. These include parts of the 2005-2007 run and the 2009-2010 run for LIGO-Virgo, and IceCube's observation periods with 22, 59 and 79 strings. We find no significant coincident events, and use the search results to derive upper limits on the rate of joint sources for a range of source emission parameters. For the optimistic assumption of …
RANDOMIZED PHASE II STUDY OF FIRST-LINE EVEROLIMUS (EVE) + BEVACIZUMAB (BEV) VERSUS INTERFERON ALFA-2A (IFN) + BEV IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC): RECORD-2
ABSTRACT Background Study results demonstrated that IFN augments BEV activity and improves median PFS in pts with mRCC. Thus, combination BEV + IFN is a standard first-line treatment option for mRCC. Combining BEV with the mTOR inhibitor EVE may be an efficacious and well-tolerated treatment option. The open-label, phase II RECORD-2 trial compared first-line EVE + BEV and IFN + BEV in mRCC. Patients and methods: Therapy-naive pts with clear cell mRCC and prior nephrectomy were randomized 1:1 to BEV 10 mg/kg IV every 2 weeks with either EVE 10 mg oral daily or IFN (9 MIU SC 3 times/week, if tolerated). Tumour assessments were every 12 weeks. Primary objective was treatment effect on progress…
A first search for coincident gravitational waves and high energy neutrinos using LIGO, Virgo and ANTARES data from 2007
A search for high-energy neutrinos coming from the direction of the Sun has been performed using the data recorded by the ANTARES neutrino telescope during 2007 and 2008. The neutrino selection criteria have been chosen to maximize the selection of possible signals produced by the self-annihilation of weakly interacting massive particles accumulated in the centre of the Sun with respect to the atmospheric background. After data unblinding, the number of neutrinos observed towards the Sun was found to be compatible with background expectations. The 90% CL upper limits in terms of spin-dependent and spin-independent WIMP-proton cross-sections are derived and compared to predictions of two sup…
Searches for violation of lepton flavour and baryon number in tau lepton decays at LHCb
Searches for the lepton flavour violating decay tau(-) -> mu(-)mu(+)mu(-) and the lepton flavour and baryon number violating decays tau(-) -> (p) over bar mu(+)mu(-) and tau(-) -> p mu(-)mu(-) have been carried out using proton-proton collision data, corresponding to an integrated luminosity of 1.0 fb(-1), taken by the LHCb experiment at root s = 7 TeV. No evidence has been found for any signal, and limits have been set at 90% confidence level on the branching fractions: B(tau(-) -> mu(-)mu(+)mu(-) mu(+)mu(-)) p mu(-)mu(-)) (p) over bar mu(+)mu(-) and tau(-) -> p mu(-)mu(-) decay modes represent the first direct experimental limits on these channels.
Erratum to: The Intensive Care Global Study on Severe Acute Respiratory Infection (ICâGLOSSARI): a multicenter, multinational, 14-day inception cohort study (Intensive Care Medicine, (2016), 42, 5, (953), 10.1007/s00134-016-4317-4)
In both the original publication (DOI 10.1007/s00134-015-4206-2) and the first erratum (DOI 10.1007/s00134-016-4317-4), the members of the IC-GLOSSARI Investigators and the ESICM Trials Group were provided in such a way that they could not be indexed as collaborators on PubMed. The publisher apologizes for these errors and is pleased to list the members of the groups here: (Table presented.).
Search for Gravitational Waves Associated with Gamma-Ray Bursts Detected by Fermi and Swift during the LIGO-Virgo Run O3a
Abbott, R., et al. (LIGO and VIRGO Collaboration)